Photosensitizers in clinical PDT

被引:839
作者
Allison, Ron R. [1 ,2 ]
Downie, Gordon H. [2 ,3 ]
Cuenca, Rosa [2 ,4 ]
Hu, Xin-Hua [1 ,2 ,5 ]
Childs, Carter J. H. [2 ,3 ]
Sibata, Claudio H. [1 ,2 ,5 ]
机构
[1] E Carolina Univ, Brody Sch Med, Dept Radiat Oncol, Greenville, NC 27858 USA
[2] E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, PDT Ctr, Greenville, NC 27858 USA
[3] E Carolina Univ, Brody Sch Med, Dept Med Pulm & Crit Care Med, Greenville, NC 27858 USA
[4] E Carolina Univ, Brody Sch Med, Dept Surg Oncol, Greenville, NC 27858 USA
[5] E Carolina Univ, Dept Phys, Greenville, NC 27858 USA
关键词
Photosensitizers; Photodynamic therapy; Review;
D O I
10.1016/S1572-1000(04)00007-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Photosensitizers in photodynamic therapy allow for the transfer and translation of light energy into a type II chemical reaction. In clinical practice, photosensitizers arise from three families-porphyrins, chlorophylls, and dyes. All clinically successful photosensitizers have the ability to a greater or lesser degree, to target specific tissues or their vasculature to achieve ablation. Each photosensitizer needs to reliably activate at a high enough light wavelength useful for therapy. Their ability to fluoresce and visualize the lesion is a bonus. Photosensitizers developed from each family have unique properties that have so far been minimally clinically exploited. This review looks at the potential benefits and consequences of each major photosensitizer that has been tried in a clinical setting. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:27 / 42
页数:16
相关论文
共 155 条
[11]   COMBINED ACTION OF PHTHALOCYANINE PHOTOSENSITIZATION AND GAMMA-RADIATION ON MAMMALIAN-CELLS [J].
BENHUR, E ;
KOL, R ;
MARKO, R ;
RIKLIS, E ;
ROSENTHAL, I .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1988, 54 (01) :21-30
[12]   SELECTIVITY OF MESO-TETRA(HYDROXYPHENYL)PORPHYRINS AND CHLORINS AND OF PHOTOFRIN-II IN CAUSING PHOTODAMAGE IN TUMOR, SKIN, MUSCLE AND BLADDER - THE CONCEPT OF COST-BENEFIT IN ANALYZING THE RESULTS [J].
BERENBAUM, MC ;
BONNETT, R ;
CHEVRETTON, EB ;
AKANDEADEBAKIN, SL ;
RUSTON, M .
LASERS IN MEDICAL SCIENCE, 1993, 8 (04) :235-243
[13]   Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma [J].
Bernstein, ZP ;
Wilson, BD ;
Oseroff, AR ;
Jones, CM ;
Dozier, SE ;
Brooks, JSJ ;
Cheney, R ;
Foulke, L ;
Mang, TS ;
Bellnier, DA ;
Dougherty, TJ .
AIDS, 1999, 13 (13) :1697-1704
[14]   Photodynamic therapy and the treatment of head and neck neoplasia [J].
Biel, MA .
LARYNGOSCOPE, 1998, 108 (09) :1259-1268
[15]   Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia - 2-year results of a randomized clinical Trial - VIP report no. 3 [J].
Blinder, KJ ;
Blumenkranz, MS ;
Bressler, NM ;
Bressler, SB ;
Donati, G ;
Lewis, H ;
Lim, JI ;
Menchini, U ;
Miller, JW ;
Mones, JM ;
Potter, MJ ;
Pournaras, C ;
Reaves, A ;
Rosenfeld, P ;
Schachat, AP ;
Schmidt-Erfurth, U ;
Sickenberg, M ;
Singerman, LJ ;
Slakter, J ;
Strong, HA ;
Virgili, G ;
Williams, GA .
OPHTHALMOLOGY, 2003, 110 (04) :667-673
[17]  
BONNETT R, 1994, P SOC PHOTO-OPT INS, V2078, P74, DOI 10.1117/12.168648
[18]   HYDROPORPHYRINS OF THE MESO-TETRA(HYDROXYPHENYL)PORPHYRIN SERIES AS TUMOR PHOTOSENSITIZERS [J].
BONNETT, R ;
WHITE, RD ;
WINFIELD, UJ ;
BERENBAUM, MC .
BIOCHEMICAL JOURNAL, 1989, 261 (01) :277-280
[19]  
BONNETT R, 1983, ADV EXP MED BIOL, V160, P241
[20]  
Bonnett R., 1989, CIBA F SYMP, V146, P40